2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
199
Breast Neoplasms
111
Carcinoma, Non-Small-Cell Lung
94
Triple Negative Breast Neoplasms
66
Neoplasm Metastasis
44
Neoplasms
42
Lung Neoplasms
25
Squamous Cell Carcinoma of Head and Neck
24
Colorectal Neoplasms
18
Stomach Neoplasms
17
Esophageal Squamous Cell Carcinoma
17
Adenocarcinoma
17
Melanoma
15
Head and Neck Neoplasms
15
Ovarian Neoplasms
12
Cholangiocarcinoma
11
Carcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Gallbladder Neoplasms
10
Esophageal Neoplasms
10
Carcinoma, Pancreatic Ductal
10
Small Cell Lung Carcinoma
9
Sarcoma
9
Fallopian Tube Neoplasms
9
Biliary Tract Neoplasms
9
Carcinoma, Squamous Cell
8
Neoplasms by Site
7
Pancreatic Diseases
6
Pancreatic Adenocarcinoma
6
Digestive System Neoplasms
6
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anal Cancer Metastatic
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled